Pro Dex
Pro Dex's revenue rose 16.4% to $78 million in fiscal 2026. Its operating margin was 16.8%, up from 16.1% a year earlier. Free cash flow was $7 million. It paid out $3 million in dividends and buybacks, 50% of free cash flow. The diluted share count fell 1.3%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Pro Dex does
Pro-Dex designs and makes surgical drivers and shavers: battery-powered and electric handheld tools that can be sterilized in an autoclave and are used mainly in orthopedic, chest and facial bone surgery. It sells mostly to medical device makers and distributors, which sell the tools under their own brands. It also provides engineering, quality and regulatory consulting to customers and makes small air motors for industry.
In fiscal 2026 it derived 98% of its revenue from medical device products and related services. Its sales depend on a few customers: its top three accounted for 92% of sales, and its largest customer alone for 78%. That customer has made purchase commitments through calendar 2028.
In February 2026 the company bought Advanced Precision Machining, a maker in Costa Mesa, California that supplies parts for aerospace and defense and for the company's own devices. It machines its medical products in Irvine, California and assembles them in Tustin, California. It was incorporated in Colorado in 1994.
Its biggest risks, as it describes them
- A large share of its sales comes from a few customers, so losing one would hurt it badly.
- Almost all its revenue comes from medical device products and related services.
- Its largest customer's purchase commitments run only through calendar 2028, with no assurance they will be extended.
- It must keep developing new and improved products to meet customers' needs.
Income statement
From fiscal 2017 to 2026, earnings per share grew 14.2% a year and net income 11.6% a year, as buybacks cut the share count by 20%.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash and short-term investments | 2 | 4 | 7 | 7 | 9 |
| Debt incl. finance leases | 14 | 13 | 12 | 15 | 18 |
| Net debt (negative means net cash) | 12 | 9 | 5 | 8 | 8 |
| Net debt to EBITDA | 2.0x | 1.3x | 0.6x | 0.7x | 0.6x |
| Debt to equity | 0.5x | 0.4x | 0.4x | 0.4x | 0.4x |
| Interest coverage | 11.0x | 10.8x | 12.8x | 12.9x | 16.0x |
| Current ratio | 2.7x | 3.2x | 2.8x | 3.2x | 4.1x |
| Quick ratio | 1.6x | 1.5x | 1.7x | 1.7x | 2.5x |
Cash flow
Projections
Project Pro Dex's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Pro Dex shares on the open market, and 3 insiders sold $2.0 million, $1.8 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 11, 2026 | Kirk Richard Lee Van JrChief Executive Officer, Director | Sold plan | 765 | $59.36 | $45,412 | Form 4 |
| Sep 9, 2026 | Kirk Richard Lee Van JrChief Executive Officer, Director | Sold plan | 19,235 | $60.58 | $1.2 million | Form 4 |
| Sep 9, 2026 | Alisha CharltonChief Financial Officer | Sold | 2,300 | $61.30 | $140,983 | Form 4 |
| May 22, 2026 | Kirk Richard Lee Van JrChief Executive Officer, Director | Sold plan | 4,128 | $62.36 | $257,438 | Form 4 |
| May 21, 2026 | Kirk Richard Lee Van JrChief Executive Officer, Director | Sold plan | 5,872 | $62.81 | $368,810 | Form 4 |
| Mar 16, 2026 | Angelita Rebamontan DomingoDirector | Sold | 998 | $47.24 | $47,146 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY24 | FY25 | FY26 |
|---|---|---|---|
| Piotroski F-score | 6 of 9 | 6 of 9 | 7 of 9 |
| Rule of 40 | — | 19.3% | 25.2% |
| Altman Z'' | 7.06 | 8.16 | 8.66 |
| Accruals ratio | −7.9% | 18.8% | 9.5% |
The nine F-score tests
| Test | FY24 | FY25 | FY26 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Fail | Pass |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Fail | Fail |
| Debt fell relative to assets | Pass | Fail | Pass |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Pass | Pass | Pass |
| Gross margin rose | Fail | Pass | Pass |
| Revenue rose relative to assets | Pass | Pass | Fail |
| F-score | 6 of 9 | 6 of 9 | 7 of 9 |
Compare
Put Pro Dex side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Pro Dex | FY26 | 16.4% | 16.8% | 8.7% | 19.6% | 0.6x | 7 | |
| Sight Sciences | FY25 | −3.1% | −48.0% | −38.7% | — | — | 5 | Compare |
| TELA Bio | FY25 | 15.8% | −42.0% | −35.7% | −190.2% | — | 4 | Compare |
| Electromed | FY26 | 15.3% | 18.8% | 11.4% | — | — | — | Compare |
| IRADIMED | FY25 | 14.4% | 31.2% | 20.5% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 22 | 22 | 27 | 35 | 38 | 42 | 46 | 54 | 67 | 78 |
| Revenue growth | 8.9% | 2.4% | 20.9% | 28.2% | 9.2% | 10.6% | 9.6% | 16.8% | 23.7% | 16.4% |
| Gross profit | 7 | 8 | 10 | 13 | 14 | 13 | 13 | 15 | 20 | 24 |
| Research and development | 1 | 2 | 2 | 2 | 4 | 3 | 3 | 3 | 4 | 3 |
| Operating income | 3 | 2 | 5 | 7 | 4 | 5 | 6 | 7 | 11 | 13 |
| Net income | 5 | 2 | 4 | 6 | 6 | 5 | 7 | 2 | 9 | 14 |
| Diluted EPS (US$) | 1.25 | 0.37 | 0.97 | 1.50 | 1.57 | 1.21 | 1.95 | 0.60 | 2.67 | 4.12 |
| Diluted shares (millions) | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 |
| Cash flow | ||||||||||
| Cash from operations | 3 | 3 | 3 | 5 | −2 | −1 | 6 | 6 | −2 | 7 |
| Capital expenditure | 1 | 1 | 1 | 0 | 2 | 2 | — | — | 1 | 0 |
| Free cash flow | 3 | 2 | 2 | 4 | −4 | −2 | — | — | −3 | 7 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 4 | 3 | 6 | 2 | 2 | 4 | 4 | 3 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 |
| Stock-based compensation | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 5 | 7 | 10 | 9 | 5 | 2 | 4 | 7 | 7 | 9 |
| Debt incl. finance leases | 0 | 0 | 5 | 4 | 13 | 14 | 13 | 12 | 15 | 18 |
| Total assets | 16 | 20 | 26 | 31 | 40 | 49 | 52 | 52 | 61 | 74 |
| Total liabilities | 3 | 3 | 8 | 12 | 20 | 24 | 20 | 22 | 25 | 27 |
| Shareholders' equity | 14 | 17 | 17 | 19 | 21 | 25 | 32 | 31 | 37 | 48 |
| Margins and ratios | ||||||||||
| Gross margin | 32.8% | 35.4% | 36.0% | 37.7% | 35.7% | 31.2% | 27.7% | 27.0% | 29.3% | 31.4% |
| Operating margin | 12.5% | 10.7% | 18.4% | 20.3% | 11.9% | 12.2% | 12.5% | 13.3% | 16.1% | 16.8% |
| Net margin | 23.2% | 7.2% | 15.3% | 17.6% | 16.2% | 10.9% | 15.3% | 4.0% | 13.5% | 17.6% |
| Free cash flow margin | 12.0% | 9.7% | 7.1% | 12.7% | −10.1% | −5.9% | — | — | −4.4% | 8.7% |
| Rule of 40 (growth + FCF margin) | 20.8% | 12.1% | 28.1% | 40.9% | −0.9% | 4.6% | — | — | 19.3% | 25.2% |
| Return on capital | 35.2% | 15.8% | 34.5% | 41.7% | 17.1% | 12.4% | 11.1% | 15.2% | 19.7% | 19.6% |
| Return on equity | 45.0% | 10.5% | 24.2% | 33.9% | 30.7% | 19.6% | 24.8% | 6.8% | 26.6% | 32.4% |
| Return on assets | 37.0% | 8.9% | 18.3% | 21.6% | 17.3% | 10.2% | 14.0% | 4.1% | 15.8% | 20.1% |
| Net debt to EBITDA | −1.5x | −2.5x | −0.9x | −0.7x | 1.5x | 2.0x | 1.3x | 0.6x | 0.7x | 0.6x |